We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
- Authors
Tomasini, Pascale; Walia, Preet; Labbe, Catherine; Jao, Kevin; Leighl, Natasha B.
- Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide. However, significant progress has been made individualizing therapy based on molecular aberrations (e.g., EGFR, ALK) and pathologic subtype. KRAS is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC), found in approximately 30% of lung adenocarcinomas, and is thus an appealing target for new therapies. Although no targeted therapy has yet been approved for the treatment of KRAS-mutant NSCLC, there are multiple potential therapeutic approaches. These may include direct inhibition of KRAS protein, inhibition of KRAS regulators, alteration of KRAS membrane localization, and inhibition of effector molecules downstream of mutant KRAS. This article provides an overview of the KRAS pathway in lung cancer and related therapeutic strategies under investigation.
- Subjects
BIOMARKERS; GENE expression; LUNG cancer; MEDLINE; GENETIC mutation; ONLINE information services; PROTEIN kinases; PROTEINS; SYSTEMATIC reviews
- Publication
Oncologist, 2016, Vol 21, Issue 12, p1450
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2015-0084